127 related articles for article (PubMed ID: 1458463)
21. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.
Vitale C; Romagnani C; Puccetti A; Olive D; Costello R; Chiossone L; Pitto A; Bacigalupo A; Moretta L; Mingari MC
Proc Natl Acad Sci U S A; 2001 May; 98(10):5764-9. PubMed ID: 11320212
[TBL] [Abstract][Full Text] [Related]
22. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
23. Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells.
Pérez-Oliva AB; Martínez-Esparza M; Vicente-Fernández JJ; Corral-San Miguel R; García-Peñarrubia P; Hernández-Caselles T
Glycobiology; 2011 Jun; 21(6):757-70. PubMed ID: 21278227
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.
Scheinberg DA; Lovett D; Divgi CR; Graham MC; Berman E; Pentlow K; Feirt N; Finn RD; Clarkson BD; Gee TS
J Clin Oncol; 1991 Mar; 9(3):478-90. PubMed ID: 1999719
[TBL] [Abstract][Full Text] [Related]
26. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
[TBL] [Abstract][Full Text] [Related]
27. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
Schirrmann T; Pecher G
Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
29. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
30. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
31. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
32. [Monoclonal antibody therapy and laboratory medicine].
Takeshita A
Rinsho Byori; 2004 Nov; 52(11):917-23. PubMed ID: 15658471
[TBL] [Abstract][Full Text] [Related]
33. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Mentz K; Singer H; Stockmeyer B; Hillen W; Mackensen A; Fey GH
MAbs; 2011; 3(1):21-30. PubMed ID: 21081841
[TBL] [Abstract][Full Text] [Related]
34. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
Sutherland MK; Yu C; Lewis TS; Miyamoto JB; Morris-Tilden CA; Jonas M; Sutherland J; Nesterova A; Gerber HP; Sievers EL; Grewal IS; Law CL
MAbs; 2009; 1(5):481-90. PubMed ID: 20065652
[TBL] [Abstract][Full Text] [Related]
35. Internalization of human macrophage surface antigens induced by monoclonal antibodies.
Audran R; Drenou B; Wittke F; Gaudin A; Lesimple T; Toujas L
J Immunol Methods; 1995 Dec; 188(1):147-54. PubMed ID: 8551032
[TBL] [Abstract][Full Text] [Related]
36. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
[No Abstract] [Full Text] [Related]
37. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Aug; 42(4):675-82. PubMed ID: 11697497
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
[TBL] [Abstract][Full Text] [Related]
40. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]